Obesity drug M&A shows yo-yo effect as acquirers wait for the next generation of medicines

The race for the next big obesity treatment is heating up, but M&A activity in the sector has hit a lull as acquirers hold out for the next generation of drugs. With high stakes and even higher valuations, the future of the market is teetering between uncertainty and opportunity.

Dive into this article where Paul Major discusses why the industry's next major deal could be just around the corner – and who’s likely to cash in.